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AbstrAct
Non-steroidal anti-inflammatory drugs (NSAIDs) are 
associated with more emergency hospital admissions 
due to adverse drug reactions than any other class of 
medicine. One way to tackle this is to ensure that patients 
understand how to take their NSAIDs in the safest way 
possible. The aim of this project was to ensure that key 
safety information is given to every patient, every time an 
NSAID is sold or dispensed. The project started as part 
of the Scottish Patient Safety Programme’s Pharmacy 
in Primary Care Collaborative. An NSAIDs bundle was 
developed, tested and implemented using the Model 
for Improvement as a framework, including multiple 
Plan, Do, Study, Act cycles. The bundle, and associated 
improvement package, was developed during phase I of 
the project and tested by seven teams (five pharmacies 
and two dispensing practices). Phase II tested the 
spread of the defined improvement package across 
an additional five community pharmacies and eight 
dispensing general practitioner practices. The project 
has resulted in the development of a simple package 
to improve communication with patients about NSAIDs, 
which should enable patients to take NSAIDs safely. Three 
key safety messages were developed, typical for a care 
bundle approach, and simple tools were employed to 
ensure every patient received these three key messages 
every time. The project aim of 95% compliance with the 
NSAIDs bundle within the seven initial sites by December 
2015 was achieved (when an exclusion was applied). The 
spread of the defined improvement package to a further 
13 sites was achieved by December 2016. By December 
2017, all 81 community pharmacies in National Health 
Service (NHS) Highland had agreed to implement the 
NSAIDs bundle. In June 2018, a national NSAIDs bundle, 
based on the NHS Highland work, was introduced in 
community pharmacies across Scotland. We also believe 
that the approach could be replicated for other high-risk 
medicines.
SecTion 1
Problem
Non-steroidal anti-inflammatory drugs 
(NSAIDs) cause preventable harm; they are 
associated with more emergency hospital 
admissions than any other class of medi-
cine.1 2 Adverse events with NSAIDs are most 
commonly associated with gastrointestinal 
(GI) ulceration and bleeding, but can also 
cause cardiovascular and renal complica-
tions.3–5 NSAIDs are one of the most commonly 
prescribed drug groups in the UK. Within the 
National Health Service (NHS) Highland in 
2016, 12.35% of the population had one or 
more prescriptions for an NSAID (approxi-
mately 41 000 out of 332 000 people). In total, 
there were 117 000 prescriptions for NSAIDs, 
costing approximately £670,000.6 Given the 
frequent use and levels of harm, there is a 
significant burden associated with NSAIDs to 
both patients and healthcare organisations.7 
This also suggests there is significant oppor-
tunity for quality improvement.
Importantly, much of the harm can be 
prevented if NSAIDs are used appropriately. 
For example, careful consideration should 
be given when prescribing NSAIDs for the 
elderly due to an increased risk of adverse 
events due to polypharmacy and associated 
alterations in pharmacokinetics.8 There are 
also increased risks of GI disturbances asso-
ciated with specific NSAID formulations and 
higher drug dosages.9 While safe prescribing 
is an essential element in reducing NSAID 
adverse events, there are also important inter-
ventions associated with patient self-care and 
administration. The focus of this project was 
to ensure patients had the correct informa-
tion to enable them to take their NSAIDs as 
safely as possible.
NHS Highland covers a population of 
332 000 people and is spread over 32 500 km2, 
which presents unique challenges in terms 
of equity of access to pharmacy services and 
associated medicine information. Pharma-
cists have a key role to play in the provision 
of medicines safety information, particu-
larly in remote and rural areas.10 In remote 
communities, general practitioner (GP) prac-
tices often provide dispensing services in the 
absence of community pharmacies. Safety 
information about NSAIDs may be regarded 
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as particularly crucial in remote areas where patients 
have reduced access to services and lengthy transfer times 
to hospital if an adverse event occurs. A local audit also 
revealed that patients in remote areas report buying more 
medicines online and do not always receive appropriate 
safety advice. Pharmaceutical community care within 
NHS Highland includes 81 community pharmacies (of 
which 52 are remote and rural) and 39 dispensing prac-
tices (37 of which are remote and rural).11 This project 
focused on remote and rural locations commencing with 
five community pharmacies and two dispensing GP prac-
tices (phase I), extending to a further five community 
pharmacies and eight dispensing GP practices (phase 
II) by December 2016. The work was initiated as part of 
the Scottish Patient Safety Programme (SPSP) Pharmacy 
in Primary Care Pilot, of which NHS Highland was one 
of four pilot sites.12 NHS Highland has an established 
history of improvement work in relation to the SPSP and 
Lean improvement methods, referred to locally as the 
Highland Quality Approach.
Background
NSAIDs are commonly used for their analgesic and 
anti-inflammatory properties in the management of pain 
relief.9 They are often selected over simple paracetamol 
due to both their lasting analgesic and anti-inflammatory 
effect. NSAIDs work by blocking cyclo-oxygenase (COX) 
enzyme, which reduces the production of prostaglandins. 
There are two types of COX: blocking COX-2 reduces the 
production of prostaglandins associated with inflamma-
tion, but blocking COX-1 reduces the production of pros-
taglandins which are important in protecting the gastric 
mucosa from the potential corrosive effects of stomach 
acid. Therefore, NSAIDs, which block the actions of 
COX-1 increase the risk of GI harm, such as ulcers and 
bleeding.13 These adverse events can also be reduced by 
patient self-management measures, including ensuring 
NSAIDs are taken with or after food, and early recogni-
tion and reporting of side effects.9 14 Another possible 
adverse event is an acute kidney injury when NSAIDs 
are taken while the patient is dehydrated.15 NHS High-
land had previously produced a Medicine Sick Day Rules 
Card, which details the medicines that should be stopped 
temporarily during periods of sickness and diarrhoea, 
with NSAIDs being one of these.16
Yet, knowledge of the risk factors associated with 
NSAIDs is limited within the general population. A study 
exploring patients’ knowledge of commonly used medica-
tions found that only 17.7% were aware of the maximum 
recommended dose of ibuprofen and only 14% were 
aware of the contraindications.17 Others have found 
that many people using NSAIDs are largely unaware 
of the potential side effects.18 This evidence is further 
supported in a survey, which found that less than 50% 
of participants knew the potential side effects of NSAIDs 
despite the majority of the sample being well educated, 
with adequate functional health literacy.19
A recent study found that there was significant variation 
in patients receiving information from pharmacies, with 
those collecting new prescriptions receiving no advice 
on 58.1% of occasions.20 A study specifically examining 
public awareness of NSAIDs found that less than 35% of 
customers had been informed by a doctor or a pharma-
cist about their use, interactions and/or potential adverse 
effects.21 Research has shown that pharmacists can 
improve medication safety by providing patient education 
about high-risk medicines.22 23 Research has suggested 
that using an information sharing tool may increase 
usage of written information by patients.24 Community 
pharmacists and dispensing practices are well placed to 
address this knowledge gap due to their location and 
frequent interactions with patients, particularly in remote 
and rural settings.
The Institute for Healthcare Improvement created 
the concept of a bundle to deliver aspects of evidence-
based practice. A bundle can be defined as a small group 
(usually no more than five items) of evidence-based 
interventions in relation to a specific aspect of care, 
which, when executed together, result in better patient 
outcomes.25 Given that there are simple interventions 
that would likely reduce patients’ risk of adverse events 
associated with NSAIDs, the team decided to devise, test 
and implement a NSAIDs bundle.
SecTion 2
Measurement
The aim of the first phase was to achieve 95% compliance 
with the NSAIDs bundle by seven community pharmacy 
and dispensing GP practice teams within NHS Highland 
by December 2015. The aim of the second phase was to 
test the spread of the NSAIDs bundle using a defined 
improvement package to a further 13 community phar-
macy and dispensing practice teams by December 2016. 
The following operational definition to measure bundle 
compliance was established: divide the number of people 
meeting the bundle standard by the total number of 
people in the sample and multiply by 100. In accordance 
with best practice, the measure was initially tested in a 
single pharmacy for 1 month to determine the feasibility 
of data collection.26 A single staff member was trained on 
the bundle and data collection procedures (November 
2014). This test identified that trying to apply all elements 
of the original bundle was problematic because the 
final two items within the bundle related solely to the 
prescribing of NSAIDs, whereas the other three could be 
applied to any supply of an NSAID (over the counter or on 
prescription). Therefore, a decision was made to separate 
these into two bundles. This project specifically reports 
on the patient information bundle (see online supple-
mentary file 1: NSAIDs bundle) and not the prescribing 
bundle.
Phase I (December 2014 to December 2015) involved 
seven teams (five pharmacies and two dispensing prac-
tices) recording bundle compliance for a random sample 
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of 10 patients a fortnight. A standardised data collection 
tool, with a dichotomous ‘yes’ or ‘no’ response, was devel-
oped and tested to ensure consistency of data collection 
(see online supplementary file 2: improvement package 
for details of data collection tool). Data were submitted 
monthly to the Quality Improvement Facilitator for colla-
tion. The Pharmacy Data Analyst created run charts. The 
Quality Improvement Facilitator returned the charts to 
the teams to discuss and display.
During phase II (January 2016 to September 2016), 
the same type of data was collected by the additional five 
community pharmacies and eight dispensing GP prac-
tices. The frequency of data collection was changed to 
weekly instead of fortnightly, as teams reported that this 
reduced confusion over whether or not the data required 
to be collected.
While bundles are designed around the concept of 
‘all or nothing’,25 data were stratified into the individual 
elements of the NSAIDs bundle to highlight the progress 
or, otherwise, of specific aspects of the bundle during 
testing. Therefore, the following elements were also 
calculated as a process measure: percentage of patients 
informed to take NSAID with or after food, percentage 
of patients informed to report any GI side effects to their 
pharmacist or GP, and finally, the percentage of patients 
given a Medicine Sick Day Rules card. All data were 
collected by peer observation and reported anonymously. 
Discrete observation within teams may assist the team to 
take ownership of the observations and data.27
deSign
Phase i: development of bundle and testing of data 
collection
The NSAIDs bundle was developed by the NHS Highland 
Scottish Patient Safety Programme Pharmacy in Primary 
Care Steering Group, which comprised representatives of 
community pharmacy, GP practices, NHS Highland and 
a patient representative. The initial step was to produce 
a driver diagram (see online supplementary file 3: driver 
diagram). A draft bundle was consulted on widely within 
NHS Highland pharmacy team and local contractor 
representative committees. Guidance was also received 
from the national SPSP Pharmacy in Primary Care Collab-
orative Steering Group.
The bundle was tested in one pharmacy for 1 month 
before testing across seven teams (five pharmacies and 
two dispensing practices). Each pharmacy identified one 
or two people to lead the project, and these were the 
‘away’ team. The away team participated in a learning 
event hosted by the National SPSP Pharmacy in Primary 
Care Collaborative, which covered an introduction to the 
Model for Improvement (MFI), the NSAIDs bundle and 
measurement. The team were encouraged to test and 
devise strategies to assist in implementing the NSAIDs 
bundle. Another learning event was held by WebEx 
3 months after the project began, the aim being for teams 
to share learning with each other. In addition, the project 
Clinical Lead and Quality Improvement Facilitator visited 
each of the seven sites to provide support within the first 
few months of the project.
Phase ii: further testing the spread of the nSaids bundle
From January 2016 to September 2016, the bundle was 
spread to a further five community pharmacies and 
a further eight dispensing GP practices. The teams 
were given the bundle, an improvement package (see 
online supplementary file 2: improvement package) and 
tools developed by the other teams during phase I. The 
teams were encouraged to test and devise their own strat-
egies to assist in implementing the NSAIDs bundle. All 
data were collected on yes/no grids and sent to the facili-
tator weekly to plot on a run chart: again, individual sites 
were provided with their own run charts as well as a High-
land-wide chart.
Additional data were collected in the eight dispensing 
GP practices only to determine whether patients under-
stood the information given. The reason for exploring 
this in dispensing practices only was because advising 
patients on medicines was a new role for practice staff, 
whereas it was something community pharmacy staff were 
more used to.
The project Clinical Lead discussed the project with all 
13 sites by telephone, followed up by a visit to launch the 
project. The Quality Improvement Facilitator also visited 
the five pharmacy sites. Ongoing support was provided by 
both the clinical lead and facilitator throughout phase II.
STraTegy and iMProveMenT cycleS
The entire project was structured using the MFI28 as 
selected by the national SPSP Pharmacy in Primary 
Care Collaborative Steering Group. The Steering Group 
provided coaching at the initial learning events for 
the collaborative, both for the NHS Highland project 
steering group and for the participating front-line teams. 
The overall structure of the project was based on part 
one of the MFI, often referred to as the three thinking 
questions. First, what are we trying to accomplish; second, 
how will we know that a change is an improvement; 
and third, what change can we make that will result in 
improvement? Teams were provided with a template of 
the MFI and encouraged to undertake Plan, Do, Study, 
Act (PDSA) cycles throughout the project (part two of 
the MFI). The following paragraphs summarise some key 
PDSA cycles, reported as a combined cycle from multiple 
teams.
PdSa cycles regarding training and awareness
All of the teams developed some form of NSAIDs 
training. The aim of the first PDSA cycle was to test 
this NSAIDs training. The hypothesis was that bundle 
compliance would improve if staff had an awareness and 
understanding of the bundle. Results of the first PDSA 
highlighted that training helped to improve bundle use, 
but that training was time consuming and not specific 
enough. In addition, teams which had only used verbal 
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training identified that backing this up with written 
information would have been useful. Subsequent PDSA 
cycles and shared learning between the sites via a WebEx 
learning event helped refine and develop a 10 minute 
NSAIDs training package, delivered verbally with written 
resources. There is evidence to suggest that educational 
interventions alone do not usually sustain change.29
PdSa cycles regarding visual prompts
The aim of these PDSA cycles was to establish an effec-
tive strategy to remind busy staff to complete the bundle. 
Initial testing of highlighting the bundle on dispensing 
labels found that while this strategy helped on occasions, 
it did not always work, as people can purchase NSAIDs 
over the counter, as opposed to receiving a prescription. 
The next stage of testing was to use Post-It notes on both 
dispensary shelves and point of sale tills as a reminder; 
however, these tended to fall off. Further testing and 
learning from PDSA cycles resulted in the creation of 
an NSAID sticker for use on the dispensary and counter 
shelves at the points of sale to act as a visual prompt to 
provide the patient with the bundle elements. The use of 
visual prompts has been used to effectively influence staff 
behaviour in other improvement projects.30
PdSa cycles nSaids information cards
The aim of this ramp of cycles was to test whether 
patients found a NSAIDs Information Card useful (see 
online supplementary file 4: NSAIDs information card). 
The idea for creating an information card came from 
the patient representative on the local SPSP Pharmacy 
Steering Group. The hypothesis was that giving patients 
written information would help them remember the 
three important messages. While patients and customers 
reported the card was useful, the card had other benefi-
cial effects. Learning from these cycles also found that the 
information card aided staff confidence in delivering the 
elements of the NSAIDs bundle. The NSAIDs informa-
tion card was subsequently used as an aide memoire for 
staff (especially for less confident or new staff) as well as 
being a tool to reiterate the verbal messages. These were 
also found to be useful for housebound patients who do 
not collect their own prescriptions from pharmacy.
SecTion 3
results
Phase I results
Figure 1 shows the run chart displaying each of the three 
elements of the NSAIDs bundle. The monthly percentage 
compliance is the combined results for all seven pilot 
sites. It is not possible to annotate the combined results as 
each site tested various strategies to improve NSAID use 
at different points along this run chart. The first strategy 
for all sites was staff training.
Both bundle elements of informing the patient to take 
the NSAID with or after food, and the reporting any GI 
side effects show a steady improvement in compliance. 
The medicine sick day rules data demonstrate more vari-
ation. Where NSAIDs are sold in pharmacies for self-lim-
iting conditions (eg, single episode of headache), it is not 
necessary, or appropriate, to provide the medicine sick 
Figure 1 Run chart displaying three stratified elements of the NSAIDs bundle during the development phase.   
GI, gastrointestinal; GP, general practitioner; NSAID, non-steroidal anti-inflammatory drug. 
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day rules advice. The advice is only needed for people 
who take NSAIDs long term. Therefore, the target of 95% 
was agreed as impossible and inappropriate to obtain 
when over-the-counter sales were included.
Phase II results
In phase II, an improvement package of the strategies 
defined within year 1 to aid implementation of the NSAIDs 
bundle was spread to the new sites. Figure 2 shows the 
run chart displaying weekly data for the initial 10 weeks 
of the NSAIDs bundle implementation after receiving the 
improvement package. These sites demonstrated a very 
quick improvement in ensuring that patients received the 
three key messages—a baseline figure of 10% to above 
90% in the space of a few weeks for bundle elements 1 
and 2. For element 3 (on medicine sick day rules), the 
figure was around 70% in community pharmacy (which 
was appropriate, as explained above) and above 95% in 
dispensing practices (where there are no sales of medi-
cines, just dispensing of prescriptions).
Phase ii, part two results (dispensing practices only)
For dispensing practice staff, advising patients about 
medicines was a completely new role. Before this project, 
dispensing practice staff checked patients’ demo-
graphic details before handing out medicines, but did 
not routinely provide advice about how to take or use 
medicines. Therefore, additional data were collected 
at eight dispensing practices to assess whether patients’ 
knowledge about how to take their NSAIDs was improved 
by the intervention.
Dispensing practice staff were trained by the project 
Clinical Lead on how to use TeachBack, a recognised 
approach to check patient understanding of informa-
tion given.31 Figure 3 shows staff-reported responses as 
to whether patients understood the information given, 
based on patient responses to a TeachBack approach. A 
dip is seen at week 9: staff reported that this was due to a 
holiday period when different staff were working in the 
dispensary to provide holiday cover. This highlighted the 
importance of ensuring all staff who work in the dispen-
sary receive appropriate training.
In addition, patients at the eight dispensing practices 
were asked to rate overall whether or not they had suffi-
cient information to take their NSAID safely. This was 
achieved by asking the patient to anonymously place a 
ball into a ‘yes’ or ‘no’ box. Balls were counted by prac-
tice staff at the end of each week. The results are shown 
in figure 4, with a universally positive response from 
patients sustained over a 12-week period, demonstrating 
that dispensing practice staff were able to successfully 
deliver advice on NSAIDs following the introduction of 
the NSAIDs bundle and improvement package.
leSSonS and liMiTaTionS
The project aim was to ensure that key information is given 
to every patient, every time an NSAID is sold or dispensed, 
Figure 2 Run chart displaying weekly data after the introduction of the non-steroidal anti-inflammatory drugs (NSAIDs) bundle 
implementation package.
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so that patients know how to take NSAIDs safely. For this 
to be achieved, there was a need to make the ‘right thing, 
the easy thing to do’. This was achieved by devising an 
NSAIDs bundle. We believe one of the key elements of 
the project’s success was encouraging the teams to test 
and devise strategies to assist in implementing the NSAIDs 
bundle within their own context. The approach empow-
ered the entire pharmacy team, rather than relying solely 
Figure 3 Run chart displaying weekly data on patient understanding of the non-steroidal anti-inflammatory drugs (NSAIDs) 
messages after the NSAIDs bundle package was introduced.
Figure 4 Chart displaying weekly outcomes data on whether patients reported having enough information to take a non-
steroidal anti-inflammatory drug (NSAID) safely after the NSAIDs bundle package was introduced.
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on the pharmacist, which is likely to have increased relia-
bility in busy community pharmacies. It also enabled the 
NSAIDs bundle to be used in dispensing practices, where 
there is no pharmacist. The development of an improve-
ment package with strategies driven by front-line staff is 
likely to have improved buy-in to the project and front-
line ownership.27
The team found PDSA cycles useful in terms of itera-
tive testing and learning before attempting to spread the 
intervention more widely. The PDSA approach is also 
likely to have contributed to increasing staff confidence 
to test various strategies to support use of the NSAIDs 
bundle. This may be due to the psychological safety 
inherent in small tests of change, as opposed to full-scale 
implementation.32 We believe that the approach taken in 
this project was the correct one; small tests of change with 
seven teams, developing an improvement package driven 
by front-line staff, testing the spread of that package on a 
small scale and then spreading more widely.
The main project limitation was in relation to outcome 
data. Although the project delivered improvements 
to processes in patients receiving consistent messages 
around NSAID safety, we have not been able to demon-
strate improvements in terms of outcome measures. 
Our ultimate aim was to reduce the number of hospital 
admissions due to adverse effects of NSAIDs, specifically 
GI effects and acute kidney injury. The reasons we have 
not been able to demonstrate this outcome measure is 
twofold: the initial pilot sites were small in number, so any 
action would not have had a statistically significant effect 
on hospital admissions; and the adverse events associated 
with NSAIDs have multifactorial causes, resulting in chal-
lenges in determining cause and effect.33 Now that the 
bundle is being rolled out across all locations with subse-
quent larger samples, a next step is to measure whether it 
has an impact on the number of hospital admissions due 
to adverse effects of NSAIDs.
Another limitation is that data were collected on a 
sample basis, so there is a potential for an inaccurate 
reflection of the overall picture. However, this bias is 
unlikely as all sites reported similar data. Although bias 
cannot be excluded due to the use of observation data, 
on balance this approach was selected due to the neces-
sity for engagement, ownership and trust with all partici-
pating teams.
Additionally, the problem with achieving compliance 
with the medicine sick day rules element of the bundle 
in community pharmacies (as already described) could 
have been overcome if the bundle had been adjusted to 
include an exclusion element. Responses to this element 
of the bundle would then be ‘yes’, ‘no’ and/or annotated 
with an ‘E’ for exclusion. This would have enabled a more 
accurate reflection of bundle implementation.
Patients in remote and rural areas rely on dispensing 
practices for supply of medicines, and therefore it is 
essential to ensure that medicines safety information 
is provided to these patients, as it should be to patients 
in urban areas via community pharmacies. A significant 
improvement achieved within the project was the trans-
formation of the role of dispensing practice staff in 
remote and rural areas. Historically, dispensing practice 
staff in these areas issued medicines without providing 
any verbal advice. Although advice was provided within 
the GP consultation, this advice was not reinforced 
at the point of dispensing or given at all during subse-
quent issues of repeat medicines. Through this project, 
dispensing practice staff reported feeling empowered 
for the first time to provide key medicines safety advice. 
Through this project, they started to provide advice on 
NSAIDs and achieved compliance with the bundle. This 
empowerment extended beyond NSAIDs, for example, 
drawing patients’ attention to pre-printed warning labels 
on dispensed medicines labels.
While improvement work is context specific,34 sharing 
the strategies tested and subsequently defined as an 
improvement package in phase I with sites in phase II 
accelerated the bundle implementation in phase II. An 
improvement pack was designed for all remaining sites to 
assist them, although the opportunity for teams to devise 
their own strategies for implementation continues to be 
encouraged.
concluSion
In summary, it was clear that before this project, patients 
were receiving limited information about the interven-
tions to reduce the risk of NSAIDs adverse events. The 
consequences of these adverse events can be serious for 
both patients and healthcare resource. Yet, simple inter-
ventions, such as the NSAIDs bundle reported in this 
project, have the potential to reduce these events.
This initiative achieved an improvement in the consis-
tency of NSAIDs patient information through a defined 
improvement package. That package has now spread to 
all pharmacies in NHS Highland. Pharmacies in four 
other Scottish NHS boards have begun testing and using 
the NSAIDs bundle. In November 2017, it was announced 
that a bundle around improving communication with 
NSAIDs would be included in the national community 
pharmacy contract in Scotland from April 2018.35 In June 
2018, a national NSAIDs communication bundle was 
published, which is based on the NHS Highland NSAIDs 
improvement package.36
We believe that this project has implications beyond 
NSAIDs. It is well known that many medicines have 
adverse effects that can be prevented if patients know 
how to take them properly and take actions to mitigate 
the risk.22 Using PDSA cycles and a bundle approach to 
communicate key safety messages could be replicated for 
other high risk medicines.
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